Shanghai Pharma 上海医药
8 significant filings since 30 May 2026: 2 on regulatory inquiry, 3 on dividend and 2 on major holder buying, and 1 other kind. The latest, on 11 Sep 2026: 上海医药集团股份有限公司2026年半年度权益分派实施公告. 1 unverified report logged, the latest on 20 Aug 2026.
自 30 May 2026 起有 8 份重大公告：regulatory inquiry 2 份、dividend 3 份、major holder buying 2 份，另有 1 类。最新一份（11 Sep 2026）：上海医药集团股份有限公司2026年半年度权益分派实施公告。记录了 1 条未经核实的报道，最新一条见于 20 Aug 2026。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 21 Feb 2023 | 国金证券 | 赵海春 | Outperform 增持 | ▲ | Buy 买入 |
| 3 May 2017 | 东吴证券 | 全铭,焦德智 | Outperform 增持 | ▲ | Buy 买入 |
| 23 Mar 2017 | 东吴证券 | 全铭,焦德智 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 信达证券 | 唐爱金,章钟涛 | Unrated | 14 Apr 2026 | 1 | — |
| 西南证券 | 杜向阳 | Unrated | 8 Apr 2026 | 1 | — |
| 中邮证券 | 盛丽华,龙永茂 | Buy 买入 | 2 Apr 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 4 reports. 每行为该券商近十二个月的最新研报；4 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。